624734-27-6

Basic information

• Product Name: 3-methyl-5,6,7,8-tetrahydro-1,6-naphthyridine
• Synonyms: 3-methyl-5,6,7,8-tetrahydro-1,6-naphthyridine;3-TrifluoroMethyl-5,6,7,8-tetrahydro-[1,6]naphthyridine hydrochloride (1:2)
• CAS NO: 624734-27-6
• Molecular Formula: C₉H₉F₃N₂
• Molecular Weight: 148.205
• Mol File: 624734-27-6.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 240℃
• Flash Point: 99℃
• Appearance: /
• Density: 1.271
• Vapor Pressure: 0.0393mmHg at 25°C
• Refractive Index: 1.475
• CAS DataBase Reference: 3-methyl-5,6,7,8-tetrahydro-1,6-naphthyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methyl-5,6,7,8-tetrahydro-1,6-naphthyridine(624734-27-6)
• EPA Substance Registry System: 3-methyl-5,6,7,8-tetrahydro-1,6-naphthyridine(624734-27-6)

Safety Data

• Hazardous Substances Data: 624734-27-6(Hazardous Substances Data)

Usage

Description

3-Methyl-5,6,7,8-tetrahydro-1,6-naphthyridine is an organic compound belonging to the naphthyridine family. It is characterized by its unique molecular structure, which features a fused six-membered and five-membered nitrogen-containing ring system with a methyl group at the third position. 3-Methyl-5,6,7,8-tetrahydro-1,6-naphthyridine has potential applications in various fields due to its chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
3-Methyl-5,6,7,8-tetrahydro-1,6-naphthyridine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of novel drugs with potential applications in treating a range of medical conditions.
Used in Central Nervous System Disorders Treatment:
3-Methyl-5,6,7,8-tetrahydro-1,6-naphthyridine is used as an aryl aminopyridine phosphodiesterase 10 inhibitor for treating central nervous system disorders. By inhibiting this enzyme, the compound can help regulate the levels of cyclic nucleotides in the brain, which play a crucial role in the functioning of the central nervous system. This makes it a promising candidate for the development of new therapies for conditions such as Alzheimer's disease, Parkinson's disease, and other neurological disorders.

InChI:InChI=1/C9H9F3N2/c10-9(11,12)7-3-6-4-13-2-1-8(6)14-5-7/h3,5,13H,1-2,4H2

Upstream product

• 33252-63-0 2-hydroxy-5-(trifluoromethyl)pyridine 
• 624734-24-3 tert-butyl 7-oxo-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-8-carboxylate 
• 624734-23-2 tert-butyl methyl [3-cyano-5-(trifluoromethyl)pyridin-2-yl]malonate 
• 624734-25-4 3-(trifluoromethyl)-5,8-dihydro-1,6-naphthyridin-7(6H)-one 
• 624734-22-1 2-chloro-5-(trifluoromethyl)pyridine-3-carbonitrile 
• 76041-73-1 3-bromo-5-(trifluoromethyl)pyridin-2-ol 
• 129904-48-9 2-hydroxy-5-(trifluoromethyl)nicotinaldehyde 
• 624734-26-5 tert-butyl 3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate 

Downstream Products

• 741736-95-8 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine, hydrochloride salt 
• 1537880-05-9 (3aR,5R,6aR)-benzyl 5-((tert-butoxycarbonyl)amino)-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate 
• 1138085-43-4 {2-[(2,4-dimethyl-benzyl)-methyl-amino]-hexahydro-pentalen-3a-yl}-(3-trifluoro-methyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone 
• 1108192-89-7 N-[2,6-dimethyl-4-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-phenyl]-3,3-dimethyl-butanamide 

Relevant articles and documents

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

2,6-Disubstituted piperiddines as modulators

The present invention is further directed to compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R16, R17, R18, R19, R20, R21 and R22 are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

AMINO HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of Formula I and Formula II: (wherein n, R 1,R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R33 R34, R35, R36, R37, R38, A, j, k, m, n, X, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.